' Momentous ' Data for First-Line Combo in Liver Cancer ' Momentous ' Data for First-Line Combo in Liver Cancer
The combination of atezolizumab and bevacizumab for the first-line treatment of unresectable hepatocellular carcinoma is set to become the new standard of care for this poor-prognosis cancer.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Avastin | Cancer | Cancer & Oncology | Carcinoma | Hematology | Hepatocellular Carcinoma | Liver | Liver Cancer | Urology & Nephrology